Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells
- PMID: 7505332
Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells
Abstract
Nimesulide (NIM) is a sulfonanilide nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of various inflammatory diseases and chemically unrelated to other acidic NSAIDs, such as acetylsalicylic acid (ASA) and indomethacin (INDO). We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC). Histamine release from basophils challenged with rabbit anti-human IgE antibody (anti-IgE) was enhanced by preincubation with ASA or INDO (92.2 +/- 7.1% at 10(-3) M and 61.1 +/- 6.7% at 3 x 10(-6) M, respectively; P < .001). In contrast, NIM and its metabolite, OH-NIM (10(-6) to 10(-3) M), caused concentration-dependent inhibition (2.9 to approximately 60% and 3.7 to approximately 90%, respectively) of IgE-mediated histamine release from basophils. NIM and OH-NIM also inhibited histamine release from basophils induced by the Ca++ ionophore A23187 and different protein kinase C activators, such as 12-O-tetradecanoyl-phorbol-13-acetate, bryostatin 1 and bryostatin 5. NIM and OH-NIM also inhibited the IgE-mediated histamine release from HLMC (52.3 +/- 9.6% and 66.1 +/- 12.1% at 10(-3) M, respectively; P < .0001) and HSMC (67.3 +/- 3.7% and 77.7 +/- 12.0% at 10(-3) M, respectively; P < .0001) but had little or no effect on HLMC and HSMC activated by A23187. NIM (10(-6) to 10(-3) M) markedly inhibited the de novo synthesis of LTC4 from basophils, LTC4 and PGD2 from HLMC and PGD2 from HSMC. NIM and OH-NIM potentiated, whereas ASA and INDO reversed, the inhibitory effect of adenylate cyclase agonists, such as prostaglandin E1 and forskolin. In addition, NIM and OH-NIM reversed the enhancing effects of ASA and INDO on IgE-mediated histamine release from basophils.
Similar articles
-
Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.J Immunol. 1990 May 15;144(10):3891-7. J Immunol. 1990. PMID: 1692065
-
The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.J Immunol. 1992 Jul 15;149(2):599-608. J Immunol. 1992. PMID: 1378071
-
Characterization of the anti-inflammatory effect of FK-506 on human mast cells.J Immunol. 1991 Dec 15;147(12):4278-85. J Immunol. 1991. PMID: 1721644
-
Mechanisms of activation of human mast cells and basophils by general anesthetic drugs.Ann Fr Anesth Reanim. 1993;12(2):116-25. doi: 10.1016/s0750-7658(05)81020-2. Ann Fr Anesth Reanim. 1993. PMID: 7690200 Review.
-
The role of basophils in allergic disease.Eur Respir J Suppl. 1996 Aug;22:126s-131s. Eur Respir J Suppl. 1996. PMID: 8871057 Review.
Cited by
-
The role of COX-2 inhibitors in pain modulation.Drugs. 2003;63 Suppl 1:1-7. doi: 10.2165/00003495-200363001-00002. Drugs. 2003. PMID: 14506906 Review.
-
Clinical pharmacokinetics of nimesulide.Clin Pharmacokinet. 1998 Oct;35(4):247-74. doi: 10.2165/00003088-199835040-00001. Clin Pharmacokinet. 1998. PMID: 9812177 Review.
-
The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.Front Immunol. 2024 Aug 12;15:1443704. doi: 10.3389/fimmu.2024.1443704. eCollection 2024. Front Immunol. 2024. PMID: 39188724 Free PMC article.
-
Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs. 1994 Sep;48(3):431-54. doi: 10.2165/00003495-199448030-00009. Drugs. 1994. PMID: 7527762 Review.
-
Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.Drug Saf. 1996 Feb;14(2):94-103. doi: 10.2165/00002018-199614020-00004. Drug Saf. 1996. PMID: 8852524 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous